JP2007512341A - 神経障害性疼痛の治療に有用なピリジン−4−イルアミン化合物 - Google Patents

神経障害性疼痛の治療に有用なピリジン−4−イルアミン化合物 Download PDF

Info

Publication number
JP2007512341A
JP2007512341A JP2006541366A JP2006541366A JP2007512341A JP 2007512341 A JP2007512341 A JP 2007512341A JP 2006541366 A JP2006541366 A JP 2006541366A JP 2006541366 A JP2006541366 A JP 2006541366A JP 2007512341 A JP2007512341 A JP 2007512341A
Authority
JP
Japan
Prior art keywords
alkyl
effective amount
halo
group
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006541366A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007512341A5 (cg-RX-API-DMAC7.html
Inventor
リム,ジヨンウオン
ブエレス,ジユリア・ケイ
ムニヨス,ベニート
プラシツト,リチヤード
ストツク,ニコラス
ベンカトラマン,シヤンカール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2007512341A publication Critical patent/JP2007512341A/ja
Publication of JP2007512341A5 publication Critical patent/JP2007512341A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C07D219/12—Amino-alkylamino radicals attached in position 9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006541366A 2003-11-21 2004-11-18 神経障害性疼痛の治療に有用なピリジン−4−イルアミン化合物 Withdrawn JP2007512341A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52473403P 2003-11-21 2003-11-21
PCT/US2004/038669 WO2005051915A1 (en) 2003-11-21 2004-11-18 Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain

Publications (2)

Publication Number Publication Date
JP2007512341A true JP2007512341A (ja) 2007-05-17
JP2007512341A5 JP2007512341A5 (cg-RX-API-DMAC7.html) 2008-01-10

Family

ID=34632928

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006541366A Withdrawn JP2007512341A (ja) 2003-11-21 2004-11-18 神経障害性疼痛の治療に有用なピリジン−4−イルアミン化合物

Country Status (7)

Country Link
US (1) US20070099950A1 (cg-RX-API-DMAC7.html)
EP (1) EP1687275A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007512341A (cg-RX-API-DMAC7.html)
CN (1) CN1882546A (cg-RX-API-DMAC7.html)
AU (1) AU2004292546A1 (cg-RX-API-DMAC7.html)
CA (1) CA2545786A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005051915A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094572B2 (en) 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
EP1891039A1 (en) * 2005-05-20 2008-02-27 Vertex Pharmaceuticals Incorporated Quinoline derivatives useful as modulators of ion channels
PL3089971T3 (pl) 2014-01-01 2021-01-25 Medivation Technologies Llc Związki i sposoby ich zastosowania
ES2960385T3 (es) * 2017-06-28 2024-03-04 Univ Osaka Tratamiento del dolor con agonista del receptor de serotonina-3
CN107721925B (zh) * 2017-09-12 2020-02-14 上海交通大学 一种新型乙酰胆碱酯酶抑制剂及其制备方法和应用
GB2568291A (en) * 2017-11-13 2019-05-15 Crisby Milita New use
CN114149410B (zh) * 2020-09-07 2025-02-25 四川科伦博泰生物医药股份有限公司 吡啶并环类化合物及其制备方法和用途
CN112300071B (zh) * 2020-11-25 2023-01-31 威胜生物医药(苏州)股份有限公司 一种高纯度磷酸氯喹的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2077249A (en) * 1934-06-06 1937-04-13 Winthrop Chem Co Inc Basically substituted acridine compounds
US3066141A (en) * 1957-04-26 1962-11-27 Jr Ralph Jones Quinoline-type mustards and process for producing same
US5021426A (en) * 1990-02-26 1991-06-04 Merck & Co., Inc. Method of traeting malaria with cyproheptadine derivatives
EP0446604A3 (en) * 1990-03-16 1992-02-19 American Cyanamid Company Pyridine and related aza heterocycle derivatives as cardiovascular agents
FR2676228B1 (fr) * 1991-05-07 1995-01-06 Rhone Poulenc Chimie Procede de preparation de sulfate de chloroquine.
EP0773716A4 (en) * 1995-06-07 1999-08-04 Cerus Corp TREATMENT OF RED BLOOD CELL SOLUTIONS WITH ANTIVRAL ACTIVE SUBSTANCES
US5783584A (en) * 1995-12-11 1998-07-21 Mayo Foundation For Medical Education And Research THA analogs useful as cholinesterase inhibitors
WO2000032175A2 (en) * 1998-12-02 2000-06-08 Pfizer Products Inc. METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY
US6194403B1 (en) * 1999-09-09 2001-02-27 Unitech Pharmaceuticals, Inc. Tacrine derivatives for treating Alzheimer's disease

Also Published As

Publication number Publication date
US20070099950A1 (en) 2007-05-03
CA2545786A1 (en) 2005-06-09
WO2005051915A1 (en) 2005-06-09
EP1687275A4 (en) 2009-01-14
EP1687275A1 (en) 2006-08-09
AU2004292546A1 (en) 2005-06-09
CN1882546A (zh) 2006-12-20

Similar Documents

Publication Publication Date Title
CN104203914B (zh) 作为lsd1抑制剂的(杂)芳基环丙胺化合物
EP0356128B1 (en) 3-(aminopropyl)methyl phosphinic acid as a therapeutic agent
US8829190B2 (en) Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
JP5743901B2 (ja) 皮膚疾患の処置のためのホスホジエステラーゼ阻害薬としてのトリアゾロピリジン誘導体
US20080249154A1 (en) Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates
JP2002521436A (ja) 置換アニリド化合物および方法
JPWO2005047286A1 (ja) スピロ複素環化合物
PT701819E (pt) Novas composicoes contendo sertralina e um agonista ou antagonista de receptor de 5-ht1d
US20100197721A1 (en) PYRROLO [3, 4-h] ISOQUINOLINE COMPOUNDS AND METHODS FOR MODULATING GATED ION CHANNELS
CZ288944B6 (cs) Derivát 5H-thiazolo[3,2-a]pyrimidinu, způsob jeho přípravy, meziprodukt pro jeho přípravu a farmaceutický prostředek, který ho obsahuje
JP2005536507A (ja) 6H−ピロロ[3,4−d]ピリダジン化合物による神経障害性疼痛の治療
HUP0204458A2 (hu) Alfa-2-antagonista hatású kinolinszármazékok és ezeket tartalmazó gyógyszerkészítmények
JP2003506437A (ja) 苦痛状態の治療のためのnmda−レセプターアンタゴニストとして有効な置換された1,5−ジヒドロピロール−2−オン誘導体
NZ238141A (en) 1,2,3,4,4a,10b-hexahydro-6-(sulphonamidophenyl)benzo(c)(1,6)naphthyridine derivatives, preparation and pharmaceutical compositions thereof
EP1056724B1 (en) Substituted cycloalkyl-4-oxonicotinic carboxamides; gaba brain receptor ligands
CA2481855A1 (en) Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
JP2008515907A (ja) チエノピリジノン化合物およびその処置方法
JP2003506436A (ja) Nmda−レセプターアンタゴニストとしての置換されたピロリジン−2,3,4−トリオン−3−オキシム誘導体
US20070099950A1 (en) Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain
KR20190117658A (ko) 7-원 아자-헤테로고리 함유 델타-오피오이드 수용체 조절 화합물, 및 그의 사용 및 제조 방법
US10053453B2 (en) Compounds and their use as BACE inhibitors
JP2001525813A (ja) ドパミンd3受容体のモジュレーターとしての置換テトラヒドロイソキノリン誘導体
US20080004272A1 (en) Compositions and methods for modulating gated ion channels
US20230226195A1 (en) Targeted aberrant alpha-synuclein species and induced ubiquitination and proteosomal clearance via co-recruitment of an e3-ligase system
US20140107153A1 (en) Therapeutic quinoline and naphthalene derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071116

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090406